Cargando…
Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine
It has been estimated that more than 390 million people are infected with Dengue virus every year; around 96 millions of these infections result in clinical pathologies. To date, there is only one licensed viral vector-based Dengue virus vaccine CYD-TDV approved for use in dengue endemic areas. Whil...
Autores principales: | Izmirly, Abdullah M., Pelletier, Adam-Nicolas, Connors, Jennifer, Taramangalam, Bhavani, Alturki, Sawsan O., Gordon, Emma A., Alturki, Sana O., Mell, Joshua C., Swaminathan, Gokul, Karthik, Vivin, Kutzler, Michele A., Kallas, Esper G., Sekaly, Rafick-Pierre, Haddad, Elias K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809550/ https://www.ncbi.nlm.nih.gov/pubmed/35061851 http://dx.doi.org/10.1371/journal.ppat.1009903 |
Ejemplares similares
-
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development
por: Alturki, Sana O., et al.
Publicado: (2020) -
Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
por: Izmirly, Abdullah M., et al.
Publicado: (2020) -
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
por: Sekaly, Rafick-Pierre
Publicado: (2008) -
Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020) -
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
por: Whitehead, Stephen S., et al.
Publicado: (2017)